OCON Therapeutics Secures Funding to Advance Drug Delivery Solutions

OCON Therapeutics has completed a $10 million investment round that will help the company advance its proprietary 3D drug delivery system, designed for treating prevalent uterine pathologies. RH Capital led the financing.

OCON Therapeutics’s validated 3D stent drug delivery frame IUB has demonstrated safety and usability in more than 150,000 women with its IUB Ballerine. The company is set to advance its IUB SEAD and IUB PRIMA assets, both designed to tackle abnormal and heavy uterine bleeding, affecting 15% of the global population (one in three women), providing long-term hormonal and short-term non-hormonal options for treatment.
 
The investment round also included support from Features Capital, Astia Angels, Exerte Partners, grants from the Israeli Innovation Authority, and other business angels, all of whom bring a wealth of expertise and a strong commitment to advancing women’s health solutions. The funding will accelerate OCON’s ongoing efforts to deliver solutions that meet the unique needs of women, addressing an overall $35 billion market opportunity while promoting better health outcomes and enhancing quality of life.
 
“Our mission at OCON Therapeutics is to create a new standard of care and give women and physicians additional choices that are safe and innovative,” OCON Therapeutics CEO Keren Leshem said. “We address the most prevalent uterine pathologies, more common than diabetes or heart disease, while ensuring targeted and lower-dose treatments to alleviate side effects and minimize risks associated with surgeries or non-compliance to oral medication.”
 
OCON has successfully completed Phase 2b clinical studies for the IUB SEAD, designed to tackle abnormal and heavy uterine bleeding. The company is preparing to initiate a U.S. pivotal study and will commence discussions with the U.S. Food and Drug Administration through its IND submission.
 
The IUB PRIMA is poised to address both long-term reversible contraception and heavy menstrual bleeding with a set-it-and-forget-it method that is highly effective for women. With a proof-of-principle working prototype, this investment allows OCON to advance the product, offering a transformative solution for women’s health that finally fit their anatomy.
 
OCON is dedicated to sustaining its legacy product, the IUB Ballerine, a leading choice for non-hormonal long-term contraception. The company is finalizing MDR regulatory activities to ensure continued availability across the European Union, South America, and Canada. The IUB Ballerine remains a preferred solution for women aged 15 to menopause, thanks to its design and proven effectiveness.

“As a leader in the industry, OCON’s financing milestone is a tremendous accomplishment for Keren and the team. Features Capital invested in OCON because we believe the IUB is a revolutionary platform for treating a variety of gynecological conditions directly at the target tissue,” Features Capital Managing Partner Jenny Barba stated. “At Features, we invest in and engage with teams to create breakthrough solutions that radically transform patient outcomes, improve health economics, and bridge health inequities in multi-billion dollar global markets. OCON’s technologies align perfectly with our thesis of Unlocking medtech.” 
 
OCON is gearing up to initiate a Series A funding round which will support expanding its product pipeline to tackle long term endometriosis treatment through its IUB STELLA and uterine fibroids using the same sustained drug-releasing platform with its IUB ADIRA. By doing so, OCON will provide healthcare professionals with a suite of products for uterine health.
 
“This latest investment is a testament of our investors’ confidence in OCON’s technology and strategic direction,” Leshem added. “We are grateful to our investors and excited to advance our clinical programs, expand our product offerings, and bring our innovative solutions to more women around the world.”
 
OCON Therapeutics is a women-led women’s health company that develops, manufactures, and commercializesg drug delivery systems based on the company’s patented IUB (Intra-Uterine Ball) platform. Recognized as a World Economic Forum Technology Pioneer, OCON is committed to providing physicians with innovations for treating the most prevalent uterine pathologies, with a focus on improving patient outcomes and experiences.